DOCSLIB.ORG

February 10-11, 2014 the Waldorf Astoria New York

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
February 10-11, 2014 the Waldorf Astoria New York February 10-11, 2014 The Waldorf Astoria New York Now in its sixteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies, with a special focus on select established private companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 35% of the biotechs who filed an IPO in 2013 will be presenting at this year’s BIO CEO & Investor Conference. 2 Hear the Washington perspective on the Affordable Care Act and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014. 6 Gain access to BIO’s 1x1 Partnering SystemTM for scouting potential investments and deal partners, optimizing your time at the event. 7 Hear presentations from more than 150 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse of the current and proposed investment trends in biotechnology. 9 Network with peers, investors, and potential partners attending the conference and our exclusive receptions. -2- Who Should Attend? Audience Profile Conference Size 1,400 One-on-One PartneringTM Meetings 1,350+ Investors Attending 700 Company Presentations 150 Market Cap >$1B+: 9% 500M-1B companies <50M 8% 300+ 24% Nearly 700 investors 250-500M 16% 50-100M 20% 100-250M 23% Rare/Genetic Therapeutic Focus Diseases: 2% Gastrointestinal Ophthalmology Disorders: 2% 2% Vaccines: 2% Diagnostics: 2% Renal: 3% 3D Metabolic: 4% Oncology 130/160/20/35 Cardiovascular 29% 4% Infectious Over 1,400 attendees Diseases: 6% CNS from 20 different countries 13% Cell Therapy/ Other Regenerative 10% Over 35% of attendees Medicine: 6% are executives Autoimmune/ Inflammation: 6% Platform/ Discovery: 9% -3- 3D 130/160/20/35 Fireside Chats Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014. Leonard Bell, M.D. CEO, Alexion Pharmaceuticals Belén Garijo, M.D. President & CEO Merck Serono Richard F. Pops Chairman & CEO Alkermes plc David E.I. Pyott Chairman of the Board & CEO Allergan Christopher A. Viehbacher CEO, Sanofi Chairman, Genzyme -4- Plenary Sessions Opening Remarks • James C. Greenwood, President & CEO, Biotechnology Industry Organization Opening Plenary: A Room with a (Buy-Side) View: The Year Ahead Monday, February 10th, 12:00pm – 12:55pm Join us for a scenic view of 2014 with portfolio managers and senior buy-side analysts. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and International Strategy & Investment (ISI). Panelists will field a range of questions on the peaks and valleys of the 2014 landscape, from valuations and volatility to challenges and opportunities facing institutional investors today. Moderator: • Mark Schoenebaum, MD, Senior Managing Director, ISI Group Panelists: • Andrew Acker, CFA, Portfolio Manager, Janus Global Life Sciences • Oleg Nodelman, Founder & Managing Director, EcoR1 Capital • William S. Slattery, Partner, Deerfield Management Company Closing Plenary: Fundraising in the New Capital Market Environment Tuesday, February 11th, 4:00pm – 4:55pm 2013 was clearly the year of the IPO. As a result, a dynamic fundraising environment emerged last year. Many biotechs took full advantage of this market to raise capital - through follow-ons and PIPEs after their initial debut. What’s next? What challenges will await these newly public companies in 2014, or those private biotechs waiting in the wings? Hear industry experts discuss why the markets are doing well and what effect it has had on the entire biotech ecosystem. What’s their advice on how can we keep the momentum, and what do biotech CEOs need to look out for in 2014? Moderator: • Jonathan L. Kravetz, Chair of the Securities Practice Group, Mintz Levin Panelists: • John Chambers, Managing Director, Head of Healthcare Investment Banking, ROTH Capital Partners • David-Alexandre Gros, MD, Executive Vice President, Chief Strategy Officer, Sanofi Speakers added daily. -5- Therapeutic Workshops Delivering the [RNAi] Goods Monday, February 10th, 10:30am - 11:25am Investing in the RNA space? What delivery technology will win the race to turn these novel molecules into ap- proved therapies? Is there a “winner take all” in this space or does each type of nucleic acid technology require a unique platform for delivery? This panel will discuss ongoing innovation in the nanoparticle, liposomal, nucleic acid, and conjugate-based approaches to delivering one of the most promising modalities in biotech. Panelists: • Douglas Fambrough, PhD, CEO, Dicerna Pharmaceuticals • Bruce Given, MD, Chief Operating Officer, Arrowhead Research Corporation • John Maraganore, PhD, Chief Executive Officer, Alnylam Pharmaceuticals • Kleanthis G. Xanthopoulos, PhD, President & CEO, Regulus Therapeutics Balancing the Risk-Reward in Rare Disease Drug Development Monday, February 10th, 2:00pm – 2:55pm There were certainly positive developments in the rare diseases space last year – as we saw with the success of recent IPOs and new deals. These possibilities of large returns often outweigh the inherent risk involved, and while the path to approval is not always as straightforward as it seems, success is there to be had. Challenges also exist throughout development however, from validating endpoints and reimbursement costs, to the difficulties of trial recruitment. How do you navigate this dynamic environment? CEOs of companies paving the way will be on-hand to discuss the advantages and challenges involved in bringing rare disease treatments to market, and industry experts will dissect some of the myths that have revolved around the space. Panelists: • Timothy R. Coté, MD, MPH, Principal & CEO, Coté Orphan Consulting • Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa Keeping an “I” on Oncology: The ASCO Immunotherapy Preview Tuesday, February 11th, 1:30pm – 2:25pm Immuno-oncology has been earning the spotlight over the past year, having been named as Science’s Breakthrough of the Year, and this year’s ASCO will be no exception. Expert panelists will discuss the latest developments in the immuno-oncology space. What will be the talk of ASCO? What does it take to get breakthrough status? Why has this field taken so long to come to fruition? Are immunotherapies the answer to managing cancer over a lifetime? Panelists: • Annalisa Jenkins, MBBS, MRCP, Executive VP & Head of Global Research and Development, Merck KGaA • Michael G. King, Jr., Senior Analyst, Biotechnology, JMP Securities • Anthony S. Marucci, Founder, President, CEO & Director, Celldex Therapeutics • Jon Wigginton, MD, Senior Vice President, Clinical Research, MacroGenics -6- Business Roundtables Solution Development: Aiming the Whole Pipeline at a Single Goal Monday, February 10th, 9:00am - 9:55am One model for maximizing biotech value creation is ‘Solution Development’, which calls for a company to develop multiple agents for a single overarching indication, either to identify the best one of many or to develop combinations. The panel will contrast this Solution Development model against the traditional model of developing a single drug for a single indication or multiple drugs but for disparate indications. How will using a Solution Development model impact clinical/regulatory strategy, competitive positioning, financing strategy, and M&A game theory? Moderator: • Peter Kolchinsky, PhD, Managing Director, RA Capital Management, LLC Panelists: • Christopher Anzalone, PhD, President & CEO, Arrowhead Research Corporation • Stanley C. Erck, President & CEO, Novavax • Milind S. Deshpande, PhD, President & CEO, Achillion Pharmaceuticals • Kurt Graves, Chairman, President & CSO, Intarcia Therapeutics The Reimbursement Landscape Under ACA Tuesday, February 11th, 12:00pm – 12:55pm The Affordable Care Act brings a great promise to the biotech industry and our nation as a whole. Now, a couple months in, what do we know? What pressure will ACA put on the forces that impact product reimbursement, and how will those forces respond? What can the biomedical ecosystem do to protect the industry’s pipelines? How did – and have - companies prepared? Come hear a discussion among industry representatives on this new environment under ACA, and get their take on where the law will lead one of the most important elements of biotech development. Panelists: • J.D. Kleinke, Healthcare Business Strategist • Laurel Todd, Managing Director, Reimbursement & Health Policy, BIO Let’s Make a Deal – Strategic Licensing and M&A Trends Tuesday, February 11th, 9:00am - 9:55am This panel will evaluate licensing and M&A trends of recent deals as the parties involved aim to get the biggest bang
Load more

Recommended publications
  • BIOWORLD TODAY Inquiry
    BIOWORLDTM TODAY THE DAILY BIOPHARMACEUTICAL NEWS SOURCE JUNE 30 , 2016 BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS VOLUME 27, NO. 126 LIPID JAM NOT OVER EASILY STOPPED FOR FUTILITY Waffle house? FDA Galena Biopharma implodes as PRESENT review fidgets endpoint, puts cancer vaccine Neuvax future in doubt outcome details; By Jennifer Boggs, Managing Editor Esperion grilled on holdup With the bulk of Galena Biopharma Inc.’s value riding on cancer vaccine Neuvax By Randy Osborne, Staff Writer (nelipepimut-S), the firm’s shares predictably plunged to a new 52-week low Wednesday as an independent data monitoring committee (IDMC) recommended the Analysts had plenty of questions but PRESENT phase III study in breast cancer be stopped for futility following a planned Esperion Therapeutics Inc. offered few interim analysis. But it’s the troubling language in the IDMC’s letter, suggesting the answers regarding the FDA’s stalling on placebo arm might actually have bested the treatment arm, that could signal the end oral, once-daily bempedoic acid (ETC- of the road for Neuvax. 1002) for lipid lowering, after the agency See Galena, page 3 See Esperion, page 4 CHINA DEALS AND M&A IN THE CLINIC Pfizer invests in Asia Merck strikes cancer SUPER ‘NOVA’ with $350M biotech vaccines deal with Tesaro shares blast plant in Hangzhou Moderna, delivering off as niraparib hits By Haky Moon, Staff Writer $200M up front PFS in ovarian cancer HONG KONG – China’s economy may By Michael Fitzhugh, Staff Writer By Marie Powers, News Editor be slowing down, but multinationals Findings from the phase III NOVA trial are positioning themselves to leverage Cancer vaccines tailored to fit tumor- specific profiles are at the heart of a new of niraparib in women with recurrent it as best they can while navigating a ovarian cancer blasted shares of still-complex regulatory environment.
    [Show full text]
  • Initiation of Francis Trial
    August 25‚ 2008 ANTHERA PHARMACEUTICALS ADVANCES GLOBAL DEVELOPMENT STRATEGY FOR VARESPLADIB IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH THE INITIATION OF FRANCIS TRIAL SAN MATEO, CA – August 25, 2008 – Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the initiation of the FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression) clinical trial designed to examine the impact of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event. The FRANCIS trial is designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It will enroll up to 500 patients that will be treated for a minimum of six months. The study will be conducted at sites in North America and Europe. FRANCIS will provide insight into the prevention of secondary Major Adverse Cardiovascular Events (MACE) over the duration of the trial. In this study, MACE is defined as a composite endpoint consisting of cardiovascular death, non-fatal stroke, non-fatal myocardial infarction, unstable angina, and a subset of revascularization following the initial event. During the course of the study, patients will receive therapeutic standard of care in addition to high dose Lipitor ® (atorvastatin). In previous clinical trials, varespladib, a potent and highly selective inhibitor of secretory phospholipase A 2 (sPLA 2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA 2, a clinically meaningful and statistically significant reduction in “bad” LDL cholesterol, and a reduction in C-reactive protein, a known marker of inflammation.
    [Show full text]
  • Tetraphase Pharmaceuticals, Inc
    WBB Securities, LLC Steve Brozak, DMH [email protected] (908) 518-7610 Tetraphase Pharmaceuticals, Inc. (NasdaqGS: TTPH) Initiating Coverage Initiating Coverage with a Speculative Buy Rating February 22, 2018 and a 12-Month Price Target of $6.00 Tetraphase Prepares for Commercialization of a Needed Antibiotic Tetraphase Pharmaceuticals, Inc. (TTPH) is Current Price $2.20 a clinical stage pharmaceutical company, 12 Month Target Price $6.00 with eravacycline as its lead candidate. It is a novel tetracycline-derived antibiotic to 12-Month Trading Range $2.05-$9.93 treat resistant and multidrug-resistant Market Capitalization (Mil) $113.50 infections, including multidrug-resistant Shares Outstanding (Mil) 51.59 Gram-negative infections. Following Avg. Daily Volume 872,642 successful IGNITE1 and IGNITE4 Phase 3 L.T. Debt (Mil) 0.00 trials in complicated intra-abdominal infections (cIAI), a New Drug Application Dividend/Yield N/A (NDA) was filed with the FDA and a Book Value P/S $2.92 Marketing Authorisation Application (MAA) was submitted to the EMA for IV NASDAQ Composite 7,218.23 eravacycline. S&P 500 2,701.33 Historical Performance and Disclosures on Page 10 - 11 Two days ago, TTPH announced an exclusive Source: QUODD+ licensing agreement with Everest Medicines Limited, a C-bridge Capital-backed biopharmaceutical company based in China, to develop and commercialize eravacycline in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore (known as the Territories). Tetraphase will receive an initial upfront payment of $7.0 million and may receive clinical and regulatory milestones of up to $16.5 million as well as a maximum of $20.0 million via achieving annual sales milestones.
    [Show full text]
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • The Top 100 November, 2016 a List of Stocks Topping Our Custom 'Torpedo’ Screen
    The Top 100 November, 2016 A list of stocks topping our custom 'torpedo’ screen. Updated monthly. GPRO GoPro, Inc. Class A Consumer Discretionary TSLA Tesla Motors, Inc. Consumer Discretionary UA Under Armour, Inc. Class A Consumer Discretionary CRC California Resources Corp Energy CRZO Carrizo Oil & Gas, Inc. Energy CWEI Clayton Williams Energy, Inc. Energy FANG Diamondback Energy, Inc. Energy GST Gastar Exploration, Inc. Energy MPLX MPLX LP Energy RSPP RSP Permian, Inc. Energy SLCA U.S. Silica Holdings, Inc. Energy AAC AAC Holdings, Inc. Health Care ABEO Abeona Therapeutics, Inc. Health Care ACAD ACADIA Pharmaceuticals Inc. Health Care ADMP Adamis Pharmaceuticals Corporation Health Care ADMS Adamas Pharmaceuticals, Inc. Health Care ADXS Advaxis, Inc. Health Care AIMT Aimmune Therapeutics Inc Health Care AKBA Akebia Therapeutics, Inc. Health Care ALDR Alder Biopharmaceuticals, Inc. Health Care ARDM Aradigm Corporation Health Care ARDX Ardelyx, Inc. Health Care ARLZ Aralez Pharmaceuticals Inc. Health Care ATRA Atara Biotherapeutics Inc Health Care BCRX BioCryst Pharmaceuticals, Inc. Health Care BLUE bluebird bio, Inc. Health Care CARA Cara Therapeutics Inc Health Care CDNA CareDx, Inc. Health Care CEMP Cempra, Inc. Health Care CERS Cerus Corporation Health Care CFMS ConforMIS Inc Health Care CLVS Clovis Oncology, Inc. Health Care COLL Collegium Pharmaceutical, Inc. Health Care CORI Corium International, Inc. Health Care CRMD CorMedix Inc. Health Care CSU Capital Senior Living Corporation Health Care DERM Dermira Inc Health Care DVAX Dynavax Technologies Corporation Health Care DXCM DexCom, Inc. Health Care EPZM Epizyme, Inc. Health Care FOLD Amicus Therapeutics, Inc. Health Care HRTX Heron Therapeutics Inc Health Care ICPT Intercept Pharmaceuticals, Inc.
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Fidelity® Extended Market Index Fund
    Quarterly Holdings Report for Fidelity® Extended Market Index Fund May 31, 2021 SEI-QTLY-0721 1.816014.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.8% Shares Value Shares Value COMMUNICATION SERVICES – 6.0% CarGurus, Inc. Class A (a) 481,276 $ 13,581,609 Diversified Telecommunication Services – 0.5% Cars.com, Inc. (a) 356,794 5,212,760 Alaska Communication Systems Group, Inc. 306,734 $ 1,018,357 Creatd, Inc. (a) (b) 42,672 156,606 Anterix, Inc. (a) (b) 65,063 3,218,016 DHI Group, Inc. (a) 262,377 839,606 ATN International, Inc. 49,421 2,336,131 Eventbrite, Inc. (a) (b) 368,036 7,471,131 Bandwidth, Inc. (a) (b) 118,706 14,041,733 EverQuote, Inc. Class A (a) (b) 54,748 1,726,204 Cincinnati Bell, Inc. (a) 265,617 4,090,502 IAC (a) 439,438 70,077,178 Cogent Communications Group, Inc. (b) 226,643 17,134,211 Izea Worldwide, Inc. (a) 258,392 718,330 Consolidated Communications Holdings, Inc. (a) 325,131 3,043,226 Kubient, Inc. (b) 44,094 228,848 Cuentas, Inc. (a) (b) 48,265 108,596 Liberty TripAdvisor Holdings, Inc. (a) 380,876 1,812,970 Globalstar, Inc. (a) (b) 3,272,215 5,235,544 Match Group, Inc. (a) 1,417,570 203,251,187 IDT Corp. Class B (a) 96,642 2,789,088 MediaAlpha, Inc. Class A (b) 91,323 3,864,789 Iridium Communications, Inc. (a) 621,382 23,743,006 Pinterest, Inc. Class A (a) 2,805,904 183,225,531 Liberty Global PLC: Professional Diversity Network, Inc.
    [Show full text]
  • NASDAQ Stock Market
    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
    [Show full text]
  • 香港知識產權公報hong Kong Intellectual Property Journal
    香港知識產權公報 Hong Kong Intellectual Property Journal 2007年7月27日 27 July 2007 公報編號 Journal No.: 225 公布日期 Publication Date: 27-07-2007 分項名稱 Section Name: 目錄 Contents * 目錄 Contents 根據專利條例第 20 條發表的指定專利申請記錄請求 Requests to Record Designated Patent Applications published under section 20 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按申請人姓名／名稱排列 Arranged by Name of Applicant 根據專利條例第 27 條發表批予標準專利 Granted Standard Patents published under section 27 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名／名稱排列 Arranged by Name of Proprietor 1/336 公報編號 Journal No.: 225 公布日期 Publication Date: 27-07-2007 分項名稱 Section Name: 目錄 Contents 根據專利條例第 118 條發表批予短期專利 Granted Short-term Patents published under section 118 of the Patents Ordinance 1. 按國際專利分類排列 Arranged by International Patent Classification 2. 按發表編號排列 Arranged by Publication Number 3. 按申請編號排列 Arranged by Application Number 4. 按專利所有人姓名／名稱排列 Arranged by Name of Proprietor 根據專利條例(第 514 章)公布的其他公告 Other Notices Published under the Patents Ordinance (Cap. 514) 根據專利條例第 20 條發表後撤回，當作已予撤回或被拒的申請 Applications Withdrawn, Deemed to have been Withdrawn, or Refused, after Publication under section 20 of the Patents Ordinance 根據專利條例第 39 條，標準專利因未繳續期費而停止有效 Standard Patents Ceased through Non-payment of Renewal Fees under section 39 of the Patents Ordinance 根據專利條例第 39(1)(b)條，標準專利
    [Show full text]
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote
    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • Example of Corresponding Structure of Excel Report, for E
    CDDW™ Faculty Conflict of Interest Disclosure The Canadian Association of Gastroenterology (CAG) must ensure balance, independence, objectivity, and scientific rigour in all educational and scientific activities. Accordingly, CDDW™ faculty members are expected to disclose to the audience any potential, apparent or actual interests or connections that appear to influence their ability to act with integrity, objectivity, and independence on the assigned task. The intent of this disclosure summary is to provide the audience with information on the faculty interests/relationships that could influence interpretations, recommendations, and conclusions. The following faculty have indicated that they do have relevant relationships of commercial interest Afif, Waqqas Janssen (Consultant) (Company Advisory Board); Abbvie (Company Advisory Board) (Research Support); Takeda (Company Advisory Board) (Consultant); Pfizer (Company Advisory Board); Merck (Company Advisory Board); Ferring (Company Advisory Board); Shire (Company Advisory Board); Prometheus (Research Support); Theradiag (Research Support) (Consultant); Buhlmann (Research Support) Anderson, John Olympus (Other); Norgine (Speaker's Bureau) Andrews, Christopher Newstrike Inc. (Research Support) (Stockholder); Newstrike Inc. (Company Advisory Board); Allergan (Research Support) (Speaker's Bureau); Allergan (Company Advisory Board); Pendopharm (Speaker's Bureau); Lupin (Company Advisory Board); Jannsen (Research Support); Medtronic (Company Advisory Board); M Pharma Inc. (Company Advisory Board)
    [Show full text]